Use of Postmastectomy Radiotherapy and Survival Rates for Breast Cancer Patients with T1–T2 and One to Three Positive Lymph Nodes

Annals of Surgical Oncology

Volumn 22, Issue 13, 2015, Pages 4295-4304

  Huo, Dezheng ^a   Hou, Ningqi ^a   Jaskowiak, Nora ^a   Winchester, David J ^b   Winchester, David P ^b   Yao, Katharine ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MASTECTOMY; MIDDLE AGED; OVERALL SURVIVAL; POSTMASTECTOMY RADIOTHERAPY; RISK FACTOR; RISK REDUCTION; VERY ELDERLY; ADJUVANT RADIOTHERAPY; ADOLESCENT; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR INVASION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODES; MASTECTOMY; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE; YOUNG ADULT;

EID: 84947129018     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-015-4528-x     Document Type: Article

References (35)

1. Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1539–69.
2. Eifel P, Axelson JA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst. 2001;93:979–89.
3. Harris JR, Halpin-Murphy P, McNeese M, Mendenhall NP, Morrow M, Robert NJ. Consensus Statement on postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys. 1999;44:989–990.
4. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. National Comprehensive Cancer Network, 2011.
5. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997;337:949–55.
6. Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999;353:1641–8.
7. Ragaz J, Olivotto IA, Spinelli JJ, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005;97:116–26.
8. Recht A, Gray R, Davidson NE, et al. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol. 1999;17:1689–700.
9. Katz A, Strom EA, Buchholz TA, et al. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol. 2000;18:2817–27.
10. Taghian A, Jeong JH, Mamounas E, et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol. 2004;22:4247–54.
11. Wallgren A, Bonetti M, Gelber RD, et al. Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol. 2003;21:1205–13.
12. Recht A, Edge SB. Evidence-based indications for postmastectomy irradiation. Surg Clin North Am. 2003;83:995–1013.
13. Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol. 2007;82:247–53.
14. Early Breast Cancer Trialists’ Collaborative Group. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383:2127–35.
15. Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15:683–90.
16. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Research Data (1973–2009), based on the November 2011 submission: National Cancer Institute, Bethesda, MD, DCCPS, Surveillance Research Program, Surveillance Systems Branch, 2012.
17. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–9.
18. Cox D. Regression models and life tables (with discussion). J R Stat Soc B. 1972;34:187–220.
19. Smith BD, Haffty BG, Hurria A, Galusha DH, Gross CP. Postmastectomy radiation and survival in older women with breast cancer. J Clin Oncol. 2006;24:4901–7.
20. Smith BD, Smith GL, Haffty BG. Postmastectomy radiation and mortality in women with T1–2 node-positive breast cancer. J Clin Oncol. 2005;23:1409–19.
21. Li Y, Moran MS, Huo Q, Yang Q, Haffty BG. Post-mastectomy radiotherapy for breast cancer patients with t1–t2 and 1–3 positive lymph nodes: a meta-analysis. PLoS One. 2013;8:e81765.
22. Kunkler IH, Canney P, van Tienhoven G, Russell NS, Group MESTM. Elucidating the role of chest wall irradiation in “intermediate-risk” breast cancer: the MRC/EORTC SUPREMO trial. Clin Oncol R Coll Radiol. 2008;20:31–4.
23. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–106.
24. Moo TA, McMillan R, Lee M, et al. Selection criteria for postmastectomy radiotherapy in t1–t2 tumors with 1 to 3 positive lymph nodes. Ann Surg Oncol. 2013;20:3169–74.
25. Tendulkar RD, Rehman S, Shukla ME, et al. Impact of postmastectomy radiation on locoregional recurrence in breast cancer patients with 1–3 positive lymph nodes treated with modern systemic therapy. Int J Radiat Oncol Biol Phys. 2012;83:e577–81.
26. McBride A, Allen P, Woodward W, et al. Locoregional recurrence risk for patients with T1–2 breast cancer with 1–3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol Biol Phys. 2014;89:392–8.
27. DaiKubicky C, Mongoue-Tchokote S. Prognostic significance of the number of positive lymph nodes in women with T1-2N1 breast cancer treated with mastectomy: should patients with 1, 2, and 3 positive lymph nodes be grouped together? Int J Radiat Oncol Biol Phys. 2013;85:1200–5.
28. Hardenbergh PH, Bentel GC, Prosnitz LR, Marks LB. Postmastectomy radiotherapy: toxicities and techniques to reduce them. Semin Radiat Oncol. 1999;9:259–68.
29. Giordano SH, Kuo YF, Freeman JL, Buchholz TA, Hortobagyi GN, Goodwin JS. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst. 2005;97:419–24.
30. Malin JL, Kahn KL, Adams J, Kwan L, Laouri M, Ganz PA. Validity of cancer registry data for measuring the quality of breast cancer care. J Natl Cancer Inst. 2002;94:835–44.
31. Du X, Freeman JL, Goodwin JS. Information on radiation treatment in patients with breast cancer: the advantages of the linked medicare and SEER data. Surveillance, Epidemiology, and End Results. J Clin Epidemiol. 1999;52:463–70.
32. Walker GV, Giordano SH, Williams M, et al. Muddy water? Variation in reporting receipt of breast cancer radiation therapy by population-based tumor registries. Int J Radiat Oncol Biol Phys. 2013;86:686–93.
33. Jagsi R, Abrahamse P, Hawley ST, Graff JJ, Hamilton AS, Katz SJ. Underascertainment of radiotherapy receipt in Surveillance, Epidemiology, and End Results registry data. Cancer. 2012;118:333–41.
34. Dragun AE, Huang B, Gupta S, Crew JB, Tucker TC. One decade later: trends and disparities in the application of post-mastectomy radiotherapy since the release of the American Society of Clinical Oncology clinical practice guidelines. Int J Radiat Oncol Biol Phys. 2012;83:e591–6.
35. Giordano SH, Lin YL, Kuo YF, Hortobagyi GN, Goodwin JS. Decline in the use of anthracyclines for breast cancer. J Clin Oncol. 2012;30:2232–9.